Register for email alerts and news feeds:
This journal | BMJ Group
rss
Emergency Medicine Journal 2005;22:734-737; doi:10.1136/emj.2005.024968
© 2005 BMJ Publishing Group Ltd and the College of Emergency Medicine.

PREHOSPITAL CARE

Prehospital activated charcoal: the way forward

S L Greene1, M Kerins2, N O’Connor3

1 Associate Specialist Clinical Toxicology, National Poisons Information Service (London), Guys and St Thomas’ NHS Trust, UK
2 Consultant in Emergency Medicine, Accident and Emergency Department, Kings College Hospital, London, UK
3 Consultant in Emergency Medicine, Accident and Emergency Department, Lady of Lourdes Hospital, Ireland

Correspondence to:
Correspondence to:
Dr S L Greene
Medical Toxicology Unit, Avonley Road, New Cross, London SE14 5ER, UK; shaun.greene{at}gstt.nhs.uk

ABSTRACT

Objectives: Single dose activated charcoal (SDAC) may be an effective method of gastric decontamination when administered to patients within an hour of drug overdose. However, few patients who may benefit from this treatment attend an emergency department within this timeframe. The authors sought to determine the current attitudes of ambulance NHS trusts to recent recommendations that the administration of SDAC should be considered as a prehospital therapy.

Methods: A postal questionnaire was used to determine the current level of use of prehospital activated charcoal by ambulance NHS trusts, the incidence of associated complications, and barriers preventing the routine use of prehospital SDAC.

Results: A completed questionnaire was returned by 36 of the 39 ambulance NHS trusts in the UK (response rate 92%). Currently none of the trusts that responded to the questionnaire provides prehospital SDAC as an intervention. The most common barriers to the provision of prehospital SDAC are the current lack of evidence in the medical literature proving it is effective in improving patient outcome and the lack of a recognised protocol for its administration. Other issues included concerns regarding potential complications, ambulance turnaround times, lack of availability of SDAC, and lack of funding.

Conclusions: A lack of published evidence proving efficacy remains the most important factor in preventing the routine administration of SDAC to appropriate patients in the prehospital environment. Further research in this setting is required to determine the usefulness of this therapy.

Abbreviations: AACT, American Academy of Clinical Toxicology; EAPCCT, European Association of Poisons Centres and Clinical Toxicologists; SDAC, single dose activated charcoal

Keywords: activated charcoal; overdose; ambulance; poisoning


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

 

The journal is co-owned by and the official journal of College of Emergency Medicine

Official journal of British Association for Immediate Care: BASICS, Faculty of Pre-Hospital Care, Irish Society for Immediate Care and Swedish Society for Emergency Medicine: SweSEM

Emergency Medicine Jobs

Emergency Medicine Jobs